NewLink continues cancer vaccine Ph III trial with interim data under wraps

An article from FierceVaccines
May 14, 2015

Without sharing interim data to prove a win for NewLink Genetics' late-stage pancreatic cancer vaccine, it will go full steam ahead on its Phase III trial, the company announced Monday.

The IMPRESS trial for algenpantucel-L--or HyperAcute pancreas--will continue with no changes following the second planned interim analysis for the trial. The analysis was tied to 444 "patient events," which typically means deaths.

Read the rest of the article here.

Common Management Taxonomy: